From indirect regulation to multi-layered metabolic control in MASLD: Multi-receptor agonism and microbiota-metabolite functional convergence.

IF 12.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Pharmacological research Pub Date : 2026-09-01 Epub Date: 2026-08-08 DOI:10.1016/j.phrs.2026.108369
Sini Zhou, Ling Dong
{"title":"From indirect regulation to multi-layered metabolic control in MASLD: Multi-receptor agonism and microbiota-metabolite functional convergence.","authors":"Sini Zhou, Ling Dong","doi":"10.1016/j.phrs.2026.108369","DOIUrl":null,"url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown clinical efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD), yet their therapeutic performance appears limited in several recurring settings, including advanced fibrosis, metabolically milder populations, and treatment discontinuation. These limitations suggest that treatment responses are shaped not only by pharmacological potency, but also by the regulatory systems through which GLP-1RAs act. Here, we propose a conceptual multi-layered framework in which GLP-1R-based therapies improve hepatic outcomes predominantly, although not exclusively, through indirect and systemic metabolic regulation. Within this framework, therapeutic responses may be influenced by the integrity of intrahepatic and systemic signaling networks, the magnitude of baseline metabolic perturbation, and the persistence of pharmacological input, which can be interpreted as structural, contextual, and temporal constraints. Multi-receptor agonists may partially mitigate these constraints by expanding regulatory inputs through glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon receptor (GCGR) co-activation. However, receptor-level modulation alone may remain insufficient to ensure durable responses after treatment withdrawal. We further discuss the gut microbiota and its metabolites as a candidate system-level regulatory layer that integrates host metabolic, immune, and endocrine signaling. Across diverse interventions, convergence appears more consistent at the level of microbiota-associated metabolic functions than taxonomic composition, but its causal significance remains incompletely established. Cross-intervention convergence analysis may therefore serve as a hypothesis-generating strategy to identify recurrent microbiota-metabolite axes with potential mechanistic and therapeutic relevance.</p>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":" ","pages":"108369"},"PeriodicalIF":12.2000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.phrs.2026.108369","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown clinical efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD), yet their therapeutic performance appears limited in several recurring settings, including advanced fibrosis, metabolically milder populations, and treatment discontinuation. These limitations suggest that treatment responses are shaped not only by pharmacological potency, but also by the regulatory systems through which GLP-1RAs act. Here, we propose a conceptual multi-layered framework in which GLP-1R-based therapies improve hepatic outcomes predominantly, although not exclusively, through indirect and systemic metabolic regulation. Within this framework, therapeutic responses may be influenced by the integrity of intrahepatic and systemic signaling networks, the magnitude of baseline metabolic perturbation, and the persistence of pharmacological input, which can be interpreted as structural, contextual, and temporal constraints. Multi-receptor agonists may partially mitigate these constraints by expanding regulatory inputs through glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon receptor (GCGR) co-activation. However, receptor-level modulation alone may remain insufficient to ensure durable responses after treatment withdrawal. We further discuss the gut microbiota and its metabolites as a candidate system-level regulatory layer that integrates host metabolic, immune, and endocrine signaling. Across diverse interventions, convergence appears more consistent at the level of microbiota-associated metabolic functions than taxonomic composition, but its causal significance remains incompletely established. Cross-intervention convergence analysis may therefore serve as a hypothesis-generating strategy to identify recurrent microbiota-metabolite axes with potential mechanistic and therapeutic relevance.

MASLD从间接调控到多层代谢控制:多受体激动作用和微生物群代谢物功能趋同。
胰高血糖素样肽-1受体激动剂(GLP-1RAs)在代谢功能障碍相关的脂肪变性肝病(MASLD)中显示出临床疗效,但其治疗效果在一些复发情况下似乎有限,包括晚期纤维化、代谢较轻的人群和停止治疗。这些局限性表明,治疗反应不仅受药理学效力的影响,还受GLP-1RAs作用的调节系统的影响。在这里,我们提出了一个概念性的多层框架,其中基于glp - 1r的治疗主要通过间接和系统性代谢调节来改善肝脏预后,尽管不是唯一的。在这一框架下,治疗反应可能受到肝内和全身信号网络的完整性、基线代谢扰动的程度和药理学输入的持久性的影响,这可以解释为结构、环境和时间限制。多受体激动剂可以通过葡萄糖依赖性胰岛素性多肽受体(GIPR)和胰高血糖素受体(GCGR)共同激活来扩大调节输入,从而部分缓解这些限制。然而,仅靠受体水平的调节可能仍不足以确保停药后的持久反应。我们进一步讨论肠道菌群及其代谢物作为整合宿主代谢、免疫和内分泌信号的候选系统级调节层。在不同的干预措施中,趋同在微生物群相关代谢功能水平上似乎比分类学组成更一致,但其因果意义仍未完全确定。因此,交叉干预趋同分析可以作为一种假设生成策略,用于识别具有潜在机制和治疗相关性的复发微生物群代谢物轴。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书